-transparent.png){kind=logo}
The value of lithium carbonate as an adjunctive treatment of resistant schizophrenia was tested in a 4-week clinical trial using a single-blind, randomized, consent design. Treatment and control groups were drawn from a population of detained patients in an English special (maximum security) hospital. The 2 groups were comparable in terms of age, sex, severity of symptoms, length of hospitalization and concurrent neuroleptic dosage. The addition of lithium carbonate to the treatment regimen did not result in symptomatic improvement in patients completing the treatment protocol. The ethical and practical difficulties raised by the trial are discussed.
Related Publications
P J Collins, and
E P Larkin, and
A P Shubsachs
April 1990,
The American journal of psychiatry,
P J Collins, and
E P Larkin, and
A P Shubsachs
June 1991,
Journal of clinical psychopharmacology,
P J Collins, and
E P Larkin, and
A P Shubsachs
March 1981,
The Journal of clinical psychiatry,
P J Collins, and
E P Larkin, and
A P Shubsachs
June 1996,
Canadian journal of psychiatry. Revue canadienne de psychiatrie,
P J Collins, and
E P Larkin, and
A P Shubsachs
April 1976,
Psychopharmacology bulletin,
P J Collins, and
E P Larkin, and
A P Shubsachs
December 1975,
The American journal of psychiatry,
P J Collins, and
E P Larkin, and
A P Shubsachs
January 1999,
Archives of general psychiatry,
P J Collins, and
E P Larkin, and
A P Shubsachs
August 1995,
The American journal of psychiatry,
P J Collins, and
E P Larkin, and
A P Shubsachs
January 1977,
Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952),
P J Collins, and
E P Larkin, and
A P Shubsachs
September 1985,
The American journal of psychiatry,
